Company profilePharmaceutical#273 of 1,318 in Pakistan3 DRAP alerts

Roche Pakistan Limited.

Pharmaceutical company · 67 brands · 79 molecules

Ranked #8 of 44 companies in Antineoplastics

67 registered products 30 pharmaceutical brands 79 distinct molecules 3 DRAP alerts

Company overview

67
registered products
30
pharmaceutical brands
79
distinct molecules
12
therapeutic classes
3
DRAP alerts

Roche Pakistan Limited. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 67 product registrations across 79 distinct molecules. Its portfolio is concentrated in Antineoplastics and Antivirals For Systemic Use. DRAP has issued 3 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Roche

17 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antivirals For Systemic Use 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

16
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20252
202614

Top molecules by brand count

Rituximab6 brands
Methoxy Polyethylene Glycol-Epoetin Beta3 brands
Bevacizumab3 brands
Peginterferon Alfa-2A2 brands
Bezafibrate2 brands
Trastuzumab2 brands
Filgrastim2 brands
Oseltamivir2 brands
Naproxen2 brands

Therapeutic classes

Antineoplastics · 10Antivirals For Systemic Use · 7Neuro · 4Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 4Immunosuppressants · 3Immunostimulants · 2Antiinflammatory And Antirheumatic Products · 2Pain Management · 2Antiepileptics · 1Gynaecological Anti-Infective & Antiseptics · 1Antimalarials · 1Lipid Modifying Agents · 1

Conditions treated

Anxiety/Depression/Insomnia · 4Pain Killers · 2Auto Immune Disease · 1General Infections · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official33 products · Rs 40.11 – Rs 270,127.02
DVAGO5 products · Rs 250 – Rs 1,629.45
Servaid16 products · Rs 45.3 – Rs 5,650
Median across source: Rs 454

Regulatory record

3 alerts in the DRAP feed we track.

Rapid Alert: Presence of Counterfeit Ocrevus 300mg/10ml Solution for Injection Manufacture
2025-01-14
Rapid Alert: Drug Product Recall: Incidents of loss and damage of vision with the off-labe
2023-09-24
Drug Safety Alert: Risk of Severe Cutaneous Adverse Reactions (SCARs) with Atezolizumab
2022-11-25

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 132 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxicillinAmoxycillin
Martin Dow Pharmaceuticals (Pvt) Ltd. holds 145 molecules not in this portfolio
AlfacalcidolAmlodipineApixabanArtemetherAspirinAzithromycin
BRYON PHARMACEUTICALS (PVT) LTD. holds 64 molecules not in this portfolio
AlbendazoleAmlodipineAtenololAtorvastatinAzithromycinAzithromycin ( Azithromycin (

Get the full profile for Roche

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.